Fröhling, Stefan

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

Levine, R. L., Wadleigh, M., Cools, J., Ebert, B. L., Wernig, G., Huntly, B. J. P., Boggon, T. J., Wlodarska, I., Clark, J. J., Moore, S., et al. (2005) · Cancer Cell

Myeloproliferative Neoplasms: Diagnosis and TreatmentAcute Myeloid Leukemia Research

Cited by 2,993

Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia

Schlenk, R. F., Döhner, K., Krauter, J., Fröhling, S., Corbacioglu, A., Bullinger, L., Habdank, M., Späth, D., Morgan, M., Benner, A., et al. (2008) · New England Journal of Medicine

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 1,628

Activating mutations in ALK provide a therapeutic target in neuroblastoma

George, R. E., Sanda, T., Hanna, M., Fröhling, S., II, W. L., Zhang, J., Ahn, Y., Zhou, W., London, W. B., McGrady, P., et al. (2008) · Nature

Neuroblastoma Research and TreatmentsNeurofibromatosis and Schwannoma Cases

Cited by 893

Accurate and efficient detection of gene fusions from RNA sequencing data

Uhrig, S., Ellermann, J., Walther, T., Burkhardt, P., Fröhlich, M., Hutter, B., Toprak, U. H., Neumann, O., Stenzinger, A., Scholl, C., et al. (2021) · Genome Research

Cancer Genomics and DiagnosticsGenomics and Phylogenetic Studies

Cited by 526

The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K

Słabicki, M., Kozicka, Z., Petzold, G., Li, Y.-D., Manojkumar, M., Bunker, R. D., Donovan, K. A., Sievers, Q. L., Koeppel, J., Suchyta, D., et al. (2020) · Nature

Protein Degradation and InhibitorsUbiquitin and proteasome pathways

Cited by 433

BCAT1 restricts αKG levels in AML stem cells leading to IDHmut-like DNA hypermethylation

Raffel, S., Falcone, M., Kneisel, N., Hansson, J., Wang, W., Lutz, C., Bullinger, L., Poschet, G., Nonnenmacher, Y., Barnert, A., et al. (2017) · Nature

Acute Myeloid Leukemia ResearchEpigenetics and DNA Methylation

Cited by 354

Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers

Horak, P., Heining, C., Kreutzfeldt, S., Hutter, B., Mock, A., Hüllein, J., Fröhlich, M., Uhrig, S., Jahn, A., Rump, A., et al. (2021) · Cancer Discovery

Cancer Genomics and DiagnosticsGenomics and Rare Diseases

Cited by 290

Small-molecule-induced polymerization triggers degradation of BCL6

Słabicki, M., Yoon, H., Koeppel, J., Nitsch, L., Roy Burman, S. S., Di Genua, C., Donovan, K. A., Sperling, A. S., Hunkeler, M., Tsai, J. M., et al. (2020) · Nature

Protein Degradation and InhibitorsUbiquitin and proteasome pathways

Cited by 270

Chromosomal Abnormalities in Cancer

Fröhling, S., & Döhner, H. (2008) · New England Journal of Medicine

Genomic variations and chromosomal abnormalitiesCancer Genomics and Diagnostics

Cited by 229

Requirement for CDK6 in MLL-rearranged acute myeloid leukemia

Placke, T., Faber, K., Nonami, A., Putwain, S. L., Salih, H. R., Heidel, F. H., Krämer, A., Root, D. E., Barbie, D. A., Krivtsov, A. V., et al. (2014) · Blood

Acute Myeloid Leukemia ResearchChromatin Remodeling and Cancer

Cited by 170

Requirement for YAP1 signaling in myxoid liposarcoma

Trautmann, M., Cheng, Y., Jensen, P., Azoitei, N., Brunner, I., Hüllein, J., Slabicki, M., Isfort, I., Cyra, M., Berthold, R., et al. (2019) · EMBO Molecular Medicine

Hippo pathway signaling and YAP/TAZSarcoma Diagnosis and Treatment

Cited by 32

Bone marrow breakout lesions act as key sites for tumor-immune cell diversification in multiple myeloma

Lutz, R., Poos, A. M., Solé-Boldo, L., John, L., Wagner, J., Prokoph, N., Baertsch, M. A., Vonficht, D., Palit, S., Brobeil, A., et al. (2025) · Science Immunology

Multiple Myeloma Research and TreatmentsBone Tumor Diagnosis and Treatments

Cited by 25

Palbociclib can overcome mutations in cyclin dependent kinase 6 that break hydrogen bonds between the drug and the protein

Hernandez Maganhi, S., Jensen, P., Caracelli, I., Zukerman Schpector, J., Fröhling, S., & Friedman, R. (2017) · Protein Science

Advanced Breast Cancer TherapiesComputational Drug Discovery Methods

Cited by 25

Selective targeting of TBXT with DARPins identifies regulatory networks and therapeutic vulnerabilities in chordoma

Umbaugh, C. S., Groth, M., Erkut, C., Lee, K.-S., Marinho, J., Linder, S., Iser, F., Kapp, J. N., Schroeter, P., Dolaner, S., et al. (2025) · Science Advances

Bone Tumor Diagnosis and TreatmentsProtein Degradation and Inhibitors

Cited by 6